This clinical trial is focused on studying a heart condition known as Atrial Fibrillation, which causes an irregular and abnormally fast heart rate. The study aims to compare the safety and how well two different treatments are tolerated. The treatments being compared are a study drug called Abelacimab (also known by its code name MAA868) and another drug called Rivaroxaban. Abelacimab is given as a solution for infusion, which means it is administered through a needle into a vein, while Rivaroxaban is taken as film-coated tablets by mouth.
The purpose of the study is to evaluate the effect of Abelacimab compared to Rivaroxaban on the rate of major or clinically relevant non-major bleeding events. Participants in the study will receive either Abelacimab or Rivaroxaban and will be monitored over a period of time to observe any bleeding events that occur. The study will help determine which treatment is safer and better tolerated for patients with atrial fibrillation.
Throughout the study, participants will be closely observed to track the time to the first occurrence of major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH). The study will also look at the time to the first occurrence of major or minor bleeding events. This information will help healthcare professionals understand the safety profile of Abelacimab compared to Rivaroxaban in managing atrial fibrillation.
Czechia 
Hungary 
Poland 
